** Disc Medicine's shares down 1.9% to $59.35 premarket as biopharma firm looks to raise equity
** Watertown, Massachusetts-based firm late Tues $200 mln offering consisting of stock and pre-funded warrants
** Co plans to use net offering proceeds to fund research and clinical development of its product candidates, to support potential commercialization of its treatment for erythropoietic protoporphyria $(EPP.UK)$, a
rare disease that causes painful sensitivity to light
** IRON shares on Tues rose nearly 4% to close at $60.52 after co received from US FDA for
** Jefferies, Leerink, Stifel and Cantor jt bookrunners for the equity offering
** Through Tues, IRON shares down 4.5% to begin 2025. Stock's 1-yr high is $77.60 (Mar 4) and 1-yr low is $25.60 (Apr 1)
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。